State Street
ARQT icon

State Street’s Arcutis Biotherapeutics ARQT Stock Holding History

State Street’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153M Sell
5,822,840
-473,357
-8% -$11M ﹤0.01% 1224
2026
Q1 		$148M Buy
6,296,197
+807,896
+15% +$20.6M 0.01% 1132
2025
Q4 		$159M Buy
5,488,301
+846,986
+18% +$21.7M 0.01% 1087
2025
Q3 		$87.5M Buy
4,641,315
+114,378
+3% +$1.8M ﹤0.01% 1408
2025
Q2 		$63.5M Buy
4,526,937
+52,734
+1% +$739K ﹤0.01% 1557
2025
Q1 		$70M Sell
4,474,203
-476,522
-10% -$6.71M ﹤0.01% 1468
2024
Q4 		$69M Sell
4,950,725
-690,906
-12% -$7.57M ﹤0.01% 1554
2024
Q3 		$52.5M Buy
5,641,631
+506,788
+10% +$5M ﹤0.01% 1687
2024
Q2 		$47.8M Sell
5,134,843
-3,649,195
-42% -$33M ﹤0.01% 1702
2024
Q1 		$87M Buy
8,784,038
+7,258,993
+476% +$54.2M ﹤0.01% 1400
2023
Q4 		$4.93M Sell
1,525,045
-2,835,762
-65% -$7.71M ﹤0.01% 2950
2023
Q3 		$23.2M Sell
4,360,807
-865,202
-17% -$7.36M ﹤0.01% 2078
2023
Q2 		$49.8M Buy
5,226,009
+1,611,228
+45% +$17.9M ﹤0.01% 1683
2023
Q1 		$39.8M Sell
3,614,781
-64,604
-2% -$935K ﹤0.01% 1801
2022
Q4 		$54.5M Buy
3,679,385
+1,024,150
+39% +$17.9M ﹤0.01% 1571
2022
Q3 		$50.7M Buy
2,655,235
+1,258,810
+90% +$28.5M ﹤0.01% 1591
2022
Q2 		$29.8M Buy
1,396,425
+206,925
+17% +$4.24M ﹤0.01% 1966
2022
Q1 		$22.9M Buy
1,189,500
+69,194
+6% +$1.17M ﹤0.01% 2295
2021
Q4 		$23.2M Buy
1,120,306
+81,093
+8% +$1.61M ﹤0.01% 2373
2021
Q3 		$24.8M Sell
1,039,213
-113,269
-10% -$2.58M ﹤0.01% 2330
2021
Q2 		$31.5M Buy
1,152,482
+184,500
+19% +$5.2M ﹤0.01% 2194
2021
Q1 		$28M Buy
967,982
+128,960
+15% +$4.03M ﹤0.01% 2142
2020
Q4 		$23.6M Buy
839,022
+573,588
+216% +$14M ﹤0.01% 2141
2020
Q3 		$7.78M Buy
265,434
+78,854
+42% +$2.11M ﹤0.01% 2573
2020
Q2 		$5.64M Buy
186,580
+19,022
+11% +$550K ﹤0.01% 2698
2020
Q1 		$4.99M Buy
+167,558
New +$4.5M ﹤0.01% 2629

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street's ARQT Position: Q2 2026 in Review

State Street reduced its Arcutis Biotherapeutics (ARQT) stake by 7.5% in Q2 2026, selling an estimated $11M and leaving 5,822,840 shares worth $153M. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

State Street first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $159M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • State Street held 5,822,840 shares of Arcutis Biotherapeutics worth $153M as of Q2 2026.
  • State Street sold 473,357 Arcutis Biotherapeutics shares in Q2 2026, an estimated $11M.
  • Arcutis Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1224 holding.
  • State Street first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • State Street's Arcutis Biotherapeutics position peaked at $159M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.